Immunopathological observations after xenogeneic liver perfusions using donor pigs transgenic for human decay-accelerating factor

Transplantation

Volumn 64, Issue 3, 1997, Pages 384-391

  Pascher, Andreas ^a   Poehlein, Christian ^a   Storck, Martin ^b   Prestel, Roland ^b   Mueller Hoecker, Josef ^c   White, David J G ^d   Abendroth, Dietmar ^b   Hammer, Claus ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DECAY ACCELERATING FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; ELECTRON MICROSCOPY; GRAFT REJECTION; HISTOPATHOLOGY; HUMAN; IMMUNOPATHOLOGY; LIVER PERFUSION; LIVER TRANSPLANTATION; NONHUMAN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SWINE; TRANSGENIC ANIMAL; XENOGRAFT;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD55; ASPARTATE AMINOTRANSFERASES; BLOOD UREA NITROGEN; COMPLEMENT ACTIVATION; COMPLEMENT PATHWAY, ALTERNATIVE; COMPLEMENT PATHWAY, CLASSICAL; ENDOTHELIUM; GRAFT REJECTION; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; PERFUSION; POTASSIUM; STAINING AND LABELING; SWINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030742317     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199708150-00002     Document Type: Article

References (37)

1. Hoofnagle JH, Carithers RL, Shapiro C, Ascher N. Fulminant hepatic failure: summary of a workshop. Hepatology 1995; 21(1): 240.
2. Harland RC, Bollinger RR. Extracorporeal hepatic perfusion in the treatment of patients with acute hepatic failure. Transpl Rev 1994; 8(2): 73.
3. Abouna GM, Fisher LMcA, Porter KA, Andres G. Experience in the treatment of hepatic failure by intermittent liver hemoperfusions. Surg Gynecol Obstet 1973; 137(5): 741.
4. Platt JL, Vercellotti GM, Dalmasso AP, et al. Transplantation of discordant xenografts: a review of progress. Immunol Today 1990; 11(2): 450.
5. Rooney IA, Liszewski MK, Atkinson JP. Leukocyte adhesion molecules in graft recognition and rejection. Xeno 1993; 1: 29.
6. Robson SC, Candinas D, Hancock WW, Wrighton C, Winkler H, Bach FH. Role of endothelial cells in transplantation. Int Arch Allergy Immunol 1995; 106: 305.
7. Oglesby T, White DJG, Tedja I, et al. Protection of mammalian cells from complement mediated lysis by transfection of human membrane cofactor protein and decay accelerating factor. Trans Assoc Am Physicians 1991; 104: 164.
8. Carrington CA, Richards AC, Cozzi E, Langford G, Yannoutsos N, White DJG. Expression of human DAF and MCP on pig endothelial cells protects from human complement. Transplant Proc 1995; 27(1): 321.
9. McCurry KR, Kooyman DL, Diamond LE, Byrne GW, Logan JS, Platt JL. Transgenic expression of human complement regulatory proteins in mice results in diminished complement deposition during organ xenoperfusion. Transplantation 1995; 59(8): 1177.
10. Yannoutsos N, Langford GA, Cozzi E, et al. Production of pigs transgenic for human regulators of complement activation. Transplant Proc 1995; 27(1): 324.
11. Cozzi E, Langford GA, Wright L, et al. Comparative analysis of human DAF expression in the tissues of transgenic pigs and man. Transplant Proc 1995; 27(1): 319.
12. Pascher A, Poehlein Ch, Stangl M, et al. Application of immunoapheresis for delaying hyperacute rejection during isolated xenogeneic pig liver perfusion. Transplantation 1997; 63(6): 867.
13. Oriol R, Barthod F, Bergemer AM, Ye Y, Koren E, Cooper DKC. Monomorphic and polymorphic carbohydrate antigens on pig tissues: implications for organ xenotransplantation in the pig-to-human model. Transplant Int 1994; 7: 405.
14. Rosengard AM, Cary NRB, Langford GA, Tucker AW, Wallwork J, White DJG. Tissue expression of human complement inhibitor, decay accelerating factor, in transgenic pigs. Transplantation 1995; 59(9): 1325.
15. Law SKA, Reid KBM. Complement. In: Male D, Rickwood D, eds. In Focus. Oxford, Washington: IRL Press, 1989.
16. Schilling A, Land W, Pratschke E, Pielsticker K, Brendel W. Dominant role of complement in the hyperacute xenograft rejection reaction. Surg Gynecol Obstet 1976; 142: 29.
17. Land W, Brendel W, Hammer C, et al. Modification of the hyperacute xenogeneic rejection. Res Exp Med (Berl) 1972; 157(3): 259.
18. Dalmasso AP, Platt JL. Prevention of complement-mediated activation of xenogeneic endothelial cells in an in vitro model of xenograft hyperacute rejection by C1 inhibitor. Transplantation 1993; 56(5): 1171.
19. Chavez-Cartaya RE, DeSola GP, Wright L, Jamieson NV, White DJG. Regulation of the complement cascade by soluble complement receptor type 1. Transplantation 1995; 59(7): 1047.
20. Pruitt SK, Kirk AD, Bollinger RR, et al. The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation 1994; 57(3): 363.
21. Xia W, Fearon DT, Kirkman RL. Effect of repetitive doses of soluble human complement receptor type 1 on survival of discordant cardiac xenografts. Transplant Proc 1993; 25(1): 410.
22. Kemp E, Dieperink H, Leth P, et al. Monoclonal antibodies to complement C3 prolong survival of discordant xenografts: guinea pig heart to rat transplantation. Transplant Proc 1994; 26(2): 1011.
23. Fodor WL, Williams BL, Matis LA, et al. Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection. Proc Natl Acad Sci USA 1994; 91: 11153.
24. Charreau B, Cassard A, Tesson L, et al. Protection of rat endothelial cells from primate complement-mediated lysis by expression of human CD59 and/or decay accelerating factor. Transplantation 1994; 58(11): 1222.
25. Langford G, Yannoutsos N, Cozzi E, et al. Production of pigs transgenic for human decay accelerating factor. Transpl Proc 1994; 26(3): 1400.
26. Schmoeckel M, Nollert G, Shahmohammadi M, et al. Prevention of hyperacute rejection by human decay accelerating factor in xenogeneic perfused working hearts. Transplantation 1996; 62(6): 729.
27. Storck M, Abendroth D, Prestel R, et al. Morphology of hDAF (CD55) transgenic pig kidneys following ex vivo hemoperfusion with human blood. Transplantation 1997; 63(2): 304.
28. Sandrin MS, Vaughan HA, Dabkowski PL, McKenzie IFC. Anti-pig IgM antibodies in human serum react predominantly with Gal(α 1-3)Gal epitopes. Proc Natl Acad Sci USA 1993; 90: 11391.
29. Makowka L, Wu GD, Hoffman A, et al. Immunopathological lesions associated with the rejection of a pig-to-human liver xenograft. Transplant Proc 1994; 26(3): 1074.
30. Bach FH. A view to the future. Transplant Proc 1993; 25(1): 25.
31. Suckfüll M, Muedsam M, Pieske O, Enders G, Babic R, Hammer C. Immunohistological studies of complement activation after xenogeneic perfusion of a working heart model. Transplant Int 1994; 7: 324.
32. Platt JL, Fischel RJ, Matas AJ, Reif SA, Bolman RM, Bach FH. Immunopathology of hyperacute xenograft rejection in a swine-to-primate model. Transplantation 1991; 52(2): 214.
33. Dalmasso AP, Vercellotti GM, Fischel RM, Bolman RM, Bach FH, Platt JL. Mechanism of complement activation in the hyperacute rejection of porcine organs transplanted into primate recipients. Am J Pathol 1992; 140(5): 1157.
34. Zhao Z, Termignon JL, Cardoso J, et al. Hyperacute xenograft rejection in the swine-to-human donor-recipient combination. Transplantation 1994; 57(2): 245.
35. Vercellotti GM, Platt JL, Bach FH, Dalmasso AP. Neutrophil adhesion to xenogeneic endothelium via iC3b. J Immunol 1991; 146(2): 730.
36. Rollins SA, Evans MJ, Johnson KK, et al. Molecular and functional analysis of porcine E-selectin reveals a potential role in xenograft rejection. Biochem Biophys Res Commun 1994; 204(2): 763.
37. Candinas D, Lesnikoski BA, Hancock WW, et al. Inhibition of platelet integrin GPIIbIIIa prolongs survival of discordant cardiac xenografts. Transplantation 1996; 62(1): 1.